Antiepileptics in migraine prophylaxis: An updated Cochrane review

Cephalalgia

Volumn 35, Issue 1, 2015, Pages 51-62

  Mulleners, Wim M ^a   McCrory, Douglas C ^b,c   Linde, Mattias ^d,e  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiepileptic; Migraine; Preventive treatment; Prophylactic treatment; Prophylaxis

Indexed keywords

ACETAZOLAMIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARISBAMATE; CLONAZEPAM; ETIRACETAM; FLUNARIZINE; GABAPENTIN; GABAPENTIN ENACARBIL; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; PREGABALIN; PROPRANOLOL; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABNORMAL THINKING; ADVERSE OUTCOME; ANOREXIA; ASTHENIA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; EPISODIC MIGRAINE; FATIGUE; FLU LIKE SYNDROME; HUMAN; META ANALYSIS (TOPIC); NAUSEA; PARESTHESIA; QUALITY OF LIFE; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW (TOPIC); TASTE DISORDER; TREATMENT RESPONSE; TREMOR; VERTIGO; MIGRAINE DISORDERS;

ANTICONVULSANTS; HUMANS; MIGRAINE DISORDERS;

EID: 84927727757     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102414534325     Document Type: Review

References (57)

1. Clarke CE, MacMillan L, Sondhi S, et al. Economic and social impact of migraine. QJM 1996;89:77-84.
2. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: A Canadian population survey. Can J Neurol Sci 1993;20:131-137.
3. Mehuys E, Paemeleire K, Van Hees T, et al. Self-medication of regular headache: A community pharmacy-based survey. Eur J Neurol 2012;19:1093-1099.
4. Steiner TJ, Stovner LJ and Birbeck GL. Migraine: The seventh disabler. Cephalalgia 2013;33:289-290.
5. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009;16:968-981.
6. Wiffen PJ, Collins S, McQuay HJ, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2010;1:CD001133.
7. Cutrer FM, Limmroth V and Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 1997;17:93-100.
8. Chronicle EP and Mulleners WM. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004;3:CD003226.
9. Linde M, Mulleners WM, Chronicle EP, et al. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010610.
10. Linde M, Mulleners WM, Chronicle EP, et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010611.
11. Linde M, Mulleners WM, Chronicle EP, et al. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010609.
12. Linde M, Mulleners WM, Chronicle EP, et al. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010608.
13. Mulleners WM and Chronicle EP. Anticonvulsants in migraine prophylaxis: A Cochrane review. Cephalalgia 2008;28:585-597.
14. Victor S and Ryan SW. Drugs for preventing migraine headaches in children. Cochrane Database Syst Rev 2003;4:CD002761.
15. Ad Hoc Committee on the Classification of Headache of the National Institute of Neurological Diseases and Blindness. Classification of headache. JAMA 1962;179:717-718.
16. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96.
17. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24(Suppl 1):1-160.
18. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: A double-blind randomized placebocontrolled study. Clin Ter 2000;151:145-148.
19. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-128.
20. Jiménez-Hernández MD, Torrecillas-Nárvaez MD and Friera-Acebal G. Eficacia y seguridadde la gabapentina en el tratamiento preventivo de la migrana [Effectiveness and safety of gabapentin in the preventive treatment of migraine] [in Spanish]. Rev Neurol 2002;35:603-606.
21. Silberstein S, Goode-Sellers S, Twomey C, et al. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia 2013;33:101-111.
22. Feuerstein T and Quebe-Fehling E. A double-blind, placebocontrolled, parallel-group, multicentre study of the safety and efficacy of gabapentin (CI-945) as a prophylactic interval therapy in patients with common migraine (protocols 879-201, -205, -206, -207, -209). Research Report No. RR 4301-00066. Freiburg: Goedecke AG Research and Development; June 25, 1990, http://dida. library.ucsf.edu/pdf/crr13j10 (accessed 1 July 2013).
23. ® (gabapentin) in migraine prophylaxis (protocol 945-217). Research report no. RR 995-00085. Morris Plains, NJ: Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Medical and Scientific Affairs Department; January 20, 2000, http://dida. library.ucsf.edu/pdf/brr13j10 (accessed 1 July 2013).
24. ® (gabapentin) in migraine prophylaxis administered in doses divided three times a day (TID) (protocol 945-220). Research report no. RR 995-00074. Morris Plains, NJ: Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Medical and Scientific Affairs Department; August 24, 1999, http://dida.library.ucsf.edu/pdf/arr13j10 (accessed 1 July 2013).
25. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004;291:965-973.
26. De Tommaso M, Marinazzo D, Nitti L, et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. Clin Neurophysiol 2007;118:2297-2304.
27. Diener HC, Tfelt-Hansen P, Dahlóf C, et al. Topiramate in migraine prophylaxis: Results from a placebocontrolled trial with propanolol as an active control. J Neurol 2004;251:943-950.
28. Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, doubleblind, placebo-controlled trial. Lancet Neurol 2007;6:1054-1062.
29. Edwards KR, Glantz MJ, Norton JA, et al. Prophylactic treatment of episodic migraine with topiramate: A double-blind, placebo-controlled trial in 30 patients. Cephalalgia 2000;20:316.
30. Gupta P, Singh S, Shukla G, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 2007;47:402-412.
31. Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study. Cephalalgia 2011;31:18-30.
32. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study. Neurol Sci 2004;25:245-250.
33. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 2004;61:490-495.
34. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: A double-blind, placebo-controlled study. Headache 2001;41:968-975.
35. Afshari D, Rafizadeh S and Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci 2012;122:60-68.
36. Ashtari F, Shaygannejad V and Akbari M. A doubleblind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008;118:301-305.
37. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31:542-559.
38. Luo N, Di W, Zhang A, et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 2012;13:80-86.
39. Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valproate in migraine prevention: A randomized blinded crossover study. Headache 2006;46:642-648.
40. Varkey E, Cider Á, Carlsson J, et al. Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls. Cephalalgia 2011;31:1428-1438.
41. Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: A randomized, placebocontrolled, double-blind 12-week pilot study. Clin Ther 2006;28:1002-1011.
42. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-1659.
43. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997;54:1141-1145.
44. Klapper J. Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia 1997;17:103-108.
45. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-286.
46. Hering R and Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo. Cephalalgia 1992;12:81-84.
47. Jensen R, Brinck T and Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: A tripleblind, placebo-controlled crossover study. Neurology 1994;44:647-651.
48. Kinze S, Clauss M, Reuter U, et al. Valproic acid is effective in migraine prophylaxis at low serum levels: A prospective open-label study. Headache 2001;41:774-778.
49. Mitsikostas DD and Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: A randomized, double-open, clinical trial. Funct Neurol 1997;12:267-276.
50. Steiner TJ, Findley LJ and Yuen A WC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:109-112.
51. Vahedi K, Taupin P, Djomby R, et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: A randomized placebo-controlled trial. J Neurol 2002;249:206-211.
52. Rompel H and Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): Results of a double-blind, cross-over study. S Afr Med J 1970;44:75-80.
53. Cady RK, Mathews N, Diener HC, et al. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009;49:216-226.
54. Stensrud P and Sjaastad O. Clonazepam (rivotril) in migraine prophylaxis. Headache 1979;19:333-334.
55. Silberstein S, Saper J, Berenson F, et al. Oxcarbazepine in migraine headache: A double-blind, randomized, placebocontrolled study. Neurology 2008;70:548-555.
56. Ghose K, Niven BE and Berry D. A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache. J Headache Pain 2002;3:79-85.
57. Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis: A double-blind randomized clinical trial. Clin Neuropharmacol 2011;34:174-177.